Click this image for the video version of this blog post.
Introduction
Hey everyone, welcome to ShareTrekk! I’m Raj, and today we’re delving into a major news item surrounding Illumina. Renowned activist investor Carl Icahn has made headlines by suing members of Illumina’s board over the controversial Grail acquisition. In this blog post, we’ll take a closer look at the key aspects of the Grail agreement, including its termination clauses, and explore the implications of this lawsuit.
The Background
To understand the significance of this lawsuit, let’s rewind a bit. When Carl Icahn first turned his attention towards Illumina, he raised some critical points in an interview. Among his allegations were claims that Illumina’s directors had demanded additional personal liability insurance before finalizing the $7.1 billion acquisition of Grail in 2021. He also alleged that the Illumina board kept shareholders in the dark about certain negative aspects of the deal, such as potential tax liabilities if the acquisition were to be unwound.
Given the turbulence that followed the board meeting, it should come as no surprise that Carl Icahn has now taken legal action, suing members of Illumina’s board. The crux of the lawsuit alleges a breach of fiduciary duties, and it has been filed in the Delaware Court of Chancery, though the details remain sealed at this point.
Carl Icahn’s Stance
In a statement, Carl Icahn mentioned that in his long career, he had never found it necessary to sue board members in this manner until now. He cited the board’s “unconscionable and egregious actions” related to closing the Grail acquisition without regulatory approval as the primary reason for his legal action.
This lawsuit comes on the heels of the European Commission’s order for Illumina to divest Grail. The company had already been fined $476 million for jumping the gun on the transaction. With a 12-month deadline for divestiture and potential extensions, the pressure is mounting. Icahn’s concern is further compounded by Illumina’s ongoing issues with the Federal Trade Commission (FTC).
Illumina’s Response
Illumina, for its part, has stated that the company is reviewing Icahn’s lawsuit. This development follows the departure of the previous CEO, Francis deSouza, and the loss of the Chairman of the board’s seat as a result of Icahn’s proxy campaign. The company has since appointed Jacob Thaysen as CEO, marking a pivotal year for Illumina.
Icahn’s faith in Illumina’s long-term potential remains unshaken, and he expressed support for the new CEO, Jacob Thaysen. It’s worth noting that Icahn now has one of his nominees on the board, indicating a shift in the company’s leadership.
Analyzing the Grail Agreement
Taking a closer look at the Grail acquisition agreement, it’s apparent that Illumina might not have secured the best deal for its shareholders. The termination clauses, in particular, provide valuable insights:
- Regulatory Approval: The agreement conditions the completion of the transaction on various factors, including the expiration or termination of waiting periods under the Hart-Scott-Rodino (HSR) Act and approval from antitrust authorities in specific jurisdictions. The agreement also mentions that no law should prevent the deal’s consummation or impose remedies on Illumina, except for “Permitted Restrictions.”
- Termination Fee: The termination fee clause outlines that Illumina would be required to pay $300 million to GRAIL if the merger agreement is terminated under specific conditions. These conditions typically relate to regulatory approval issues. Additionally, GRAIL could request an additional $300 million if certain termination conditions are met.
Financial Ramifications
Considering the financial aspect, it’s evident that the Grail acquisition has weighed on Illumina’s resources. The company’s cash and cash equivalents have decreased from $2 billion at the start of 2023 to $1.55 billion at the end of Q2, 2023. This is despite the success of their Novaseq X.
Illumina’s revenue growth projections have been revised downward to just 1%, which has had a negative impact on their stock prices. Charles Dadswell, the interim CEO, mentioned challenges in the second half of the year, with cautious customers, a protracted recovery in China, and a decline in high throughput consumables as customers transition to the NovaSeq X.
Analysts anticipate Q2, 2023 results to show revenue of $1.13 billion and an EPS of $0.129.
Future Outlook
The Grail acquisition appears to have placed Illumina in a difficult position. While they have completed the acquisition, they are still obligated to provide 2.5 years of funding to meet GRAIL’s current plan, as stipulated by the EU. The future hinges on the company’s ability to negotiate with the EU and potentially salvage a part of the hefty fine.
The question of whether they will make a loss on divesting Grail and how they choose to divest it remains uncertain. The potential issuance of Grail shares to existing shareholders might hide losses, but it’s a complex matter.
Moreover, if Carl Icahn’s lawsuit succeeds, there are questions about whether the insurance company will cover damages or if derivative actions will come into play.
The most intriguing aspect is the possibility of Illumina, once freed from Grail, resuming its core business and restoring its valuation. This might not happen until the third quarter of 2024, and until these uncertainties are resolved, the company’s shares may continue to languish.
As the lawsuit unfolds and more details become available, we’ll gain a clearer picture of its impact on Illumina’s stock price. Based on the sequence of events and the terms of the Grail deal, it’s reasonable to say that Carl Icahn’s concerns are justified on behalf of the shareholders.
In conclusion, this lawsuit against Illumina’s board reflects the complexity of corporate acquisitions, the regulatory challenges, and the financial consequences that can result from such high-stakes endeavors. As investors and stakeholders await further developments, uncertainty surrounds the future of Illumina and its path to recovery.
Stay tuned for more updates on this unfolding story. Thanks for reading, and we’ll be back with more insights soon! Goodbye for now.
Sharetreck - Tracking Genomic Investments & clinical trials for HIV. 